Imperial College London

ProfessorRogerGunn

Faculty of MedicineDepartment of Brain Sciences

Professor of Molecular Neuroimaging
 
 
 
//

Contact

 

r.gunn

 
 
//

Location

 

Burlington DanesHammersmith Campus

//

Summary

 

Summary

Roger Gunn is Professor of Molecular Neuroimaging in the Division of Brain Sciences at Imperial College London. Professor Gunn has a background in applied mathematics and his research focuses on the application of positron emission tomography (PET) and magnetic resonance imaging (MRI) technologies to the study of pathophysiology and drug development in humans. A particular focus is the development of molecular PET probes to image targets in the brain - this includes the discovery and validation of the novel probes themselves, the associated development of quantitative analysis methods and the application of these tools in clinical studies exploring disease processes and their treatment.

Professor Gunn received his undergraduate training in applied mathematics and a PhD in bio-mathematical modelling of Positron Emission Tomography (PET) data from the University of Warwick.  He has worked previously at the MRC Cyclotron Unit (London, UK),  held a faculty position at McGill University where he worked at the Montreal Neurological Institute before joining GSK in 2003 to help establish their Clinical Imaging Centre.In October 2011 he took up the position of Chief Scientific Officer and Head of Analysis at Imanova which is a joint venture between Imperial, UCL, Kings and the MRC targeted at providing high quality R&D imaging capabilities to the London Universities and Commercial organisations. He also holds a Visiting Professorship at Oxford University (Department of Engineering Science) and has published 120 peer reviewed journal articles in the field of imaging. Professor Gunn has served as a panel member for the MRC and on organising and programme committees at numerous conferences - he was recently Co-Chair of BrainPET 2011.

Publications

Journals

Onwordi EC, Halff EF, Whitehurst T, et al., Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats, Nature Communications, ISSN:2041-1723

Wilson H, Dervenoulas G, Pagano G, et al., 2019, Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study., Brain, Vol:142, Pages:3116-3128

Piccini P, Pagano G, Politis M, 2019, Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease, Movement Disorders, Vol:34, ISSN:0885-3185, Pages:1505-1515

Conference

Wilson H, Dervenoulas G, Pagano G, et al., 2019, Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's Disease: An in vivo [11C]BU99008 PET study, International Congress of Parkinson's Disease and Movement Disorders, WILEY, Pages:S835-S836, ISSN:0885-3185

Wilson H, Niccolini F, Dervenoulas G, et al., 2019, Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington's Disease: An in vivo [11C]BU99008 PET study, International Congress of Parkinson's Disease and Movement Disorders, WILEY, Pages:S836-S836, ISSN:0885-3185

More Publications